Bharat Biotech has said that its nasal vaccine against Covid-19, iNCOVACC, would be available to the public from the fourth week of January. The Hyderabad-based biotechnology company said that the vaccine will cost 800 rupees for private markets and 325 rupees for governments.
Bharat Biotech’s INCOVACC is the world’s first intranasal Covid vaccine to receive approval for the primary 2-dose schedule as well as a heterologous booster dose. The nasal vaccine will be rolled out as a booster dose for those above 18 years of age. iNCOVACC has been developed by Bharat Biotech in partnership with America’s Washington University.